Literature DB >> 19290689

Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.

Kenneth M Carpenter1, Huiping Jiang, Maria A Sullivan, Adam Bisaga, Sandra D Comer, Wilfrid Noel Raby, Adam C Brooks, Edward V Nunes.   

Abstract

This study investigated the process of change by modeling transitions among four clinical states encountered in 64 detoxified opiate-dependent individuals treated with daily oral naltrexone: no opiate use, blocked opiate use (i.e., opiate use while adhering to oral naltrexone), unblocked opiate use (i.e., opiate use after having discontinued oral naltrexone), and treatment dropout. The effects of baseline characteristics and two psychosocial interventions of differing intensity, behavioral naltrexone therapy (BNT) and compliance enhancement (CE), on these transitions were studied. Participants using greater quantities of opiates were more likely than other participants to be retained in BNT relative to CE. Markov modeling indicated a transition from abstinence to treatment dropout was approximately 3.56 times greater among participants in CE relative to participants in BNT, indicating the more comprehensive psychosocial intervention kept participants engaged in treatment longer. Transitions to stopping treatment were more likely to occur after unblocked opiate use in both treatments. Continued opiate use while being blocked accounted for a relatively low proportion of transitions to abstinence and may have more deleterious effects later in a treatment episode. (PsycINFO Database Record (c) 2009 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19290689      PMCID: PMC2832469          DOI: 10.1037/a0013049

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  19 in total

1.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.

Authors:  K M Carroll; S A Ball; C Nich; P G O'Connor; D A Eagan; T L Frankforter; E G Triffleman; J Shi; B J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2001-08

Review 2.  Contingency management for treatment of substance use disorders: a meta-analysis.

Authors:  Michael Prendergast; Deborah Podus; John Finney; Lisa Greenwell; John Roll
Journal:  Addiction       Date:  2006-11       Impact factor: 6.526

Review 3.  Markov transition models for binary repeated measures with ignorable and nonignorable missing values.

Authors:  Steven Shoptaw; Thomas R Belin
Journal:  Stat Methods Med Res       Date:  2007-08       Impact factor: 3.021

4.  Multi-state models and diabetic retinopathy.

Authors:  G Marshall; R H Jones
Journal:  Stat Med       Date:  1995-09-30       Impact factor: 2.373

5.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

6.  Cues, consequences and therapeutic talk: effects of social context and coping statements on pain.

Authors:  S C Hayes; M R Wolf
Journal:  Behav Res Ther       Date:  1984

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 8.  Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.

Authors:  Björn Axel Johansson; Mats Berglund; Anna Lindgren
Journal:  Addiction       Date:  2006-04       Impact factor: 6.526

9.  Management of relapse in naltrexone maintenance for heroin dependence.

Authors:  Maria A Sullivan; Fatima Garawi; Adam Bisaga; Sandra D Comer; Kenneth Carpenter; Wilfrid N Raby; Stephen J Anen; Adam C Brooks; Huiping Jiang; Evaristo Akerele; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2007-08-02       Impact factor: 4.492

10.  Behavioral family counseling and naltrexone for male opioid-dependent patients.

Authors:  William Fals-Stewart; Timothy J O'Farrell
Journal:  J Consult Clin Psychol       Date:  2003-06
View more
  9 in total

Review 1.  Quality of life as an outcome of opioid use disorder treatment: A systematic review.

Authors:  Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-02-10

2.  Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Authors:  Adam C Brooks; Sandra D Comer; Maria A Sullivan; Adam Bisaga; Kenneth M Carpenter; Wilfrid M Raby; Elmer Yu; Charles P O'Brien; Edward V Nunes
Journal:  J Clin Psychiatry       Date:  2010-07-13       Impact factor: 4.384

3.  The association between naltrexone treatment and symptoms of depression in opioid-dependent patients.

Authors:  David J Mysels; Wendy Y Cheng; Edward V Nunes; Maria A Sullivan
Journal:  Am J Drug Alcohol Abuse       Date:  2010-12-30       Impact factor: 3.829

4.  Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.

Authors:  Maria A Sullivan; Adam Bisaga; Andrew Glass; Kaitlyn Mishlen; Martina Pavlicova; Kenneth M Carpenter; John J Mariani; Frances R Levin; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2014-12-09       Impact factor: 4.492

5.  Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Authors:  Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga
Journal:  Am J Addict       Date:  2017-03-22

6.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

7.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

8.  Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?

Authors:  Edward V Nunes; Evgeny Krupitsky; Walter Ling; Jacqueline Zummo; Asli Memisoglu; Bernard L Silverman; David R Gastfriend
Journal:  J Addict Med       Date:  2015 May-Jun       Impact factor: 3.702

Review 9.  A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction.

Authors:  Karen Dugosh; Amanda Abraham; Brittany Seymour; Keli McLoyd; Mady Chalk; David Festinger
Journal:  J Addict Med       Date:  2016 Mar-Apr       Impact factor: 3.702

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.